Literature DB >> 11443567

Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia.

H L Preas1, E S Nylen, R H Snider, K L Becker, J C White, J M Agosti, A F Suffredini.   

Abstract

Calcitonin precursor (CTpr) levels are both markers and mediators of inflammation. The duration of their elevation after intravenous endotoxin challenge and the effects of anti-inflammatory therapies were studied in 52 subjects. CTpr levels maximized at 24 h in all subjects. At 7 days (n=4), after levels of acute-phase cytokines and C-reactive protein had normalized, CTpr levels remained 2-4-fold above baseline levels. The elimination half-life of CTpr levels ranged from 26.9 to 45.7 h. At 24 h, endotoxin and ibuprofen (compared with endotoxin alone) increased CTpr levels approximately 2-fold (P=.03), whereas soluble tumor necrosis factor receptor blunted the increase in CTpr levels by 2-3-fold (P=.0015). However, soluble interleukin-1 receptor failed to alter the increase in CTpr levels. Thus, the fact that anti-inflammatory agents may alter CTpr levels resulting from a single stimulus must be considered when CTpr is used as a clinical marker. Of importance, this study reveals that anti-inflammatory agents may modulate the CTpr level, which is a potential toxic mediator of inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443567     DOI: 10.1086/322031

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Immune regulation of procalcitonin: a biomarker and mediator of infection.

Authors:  G N Matwiyoff; J D Prahl; R J Miller; J J Carmichael; D E Amundson; G Seda; M Daheshia
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

Review 2.  Use of plasma procalcitonin levels as an adjunct to clinical microbiology.

Authors:  David N Gilbert
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

3.  Prohormones: novel biomarkers for corticosteroids in septic shock?

Authors:  Djillali Annane
Journal:  Intensive Care Med       Date:  2007-12-14       Impact factor: 17.440

Review 4.  Procalcitonin: present and future.

Authors:  H H Liu; J B Guo; Y Geng; L Su
Journal:  Ir J Med Sci       Date:  2015-07-10       Impact factor: 1.568

Review 5.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

6.  Procalcitonin as a postmortem sepsis marker. A comparison of the validity of results obtained from blood serum, aqueous humour and cerebrospinal fluid.

Authors:  S Schmidt; M Windgassen; J-R Nofer; H Pfeiffer; S Ribbecke; A Schmeling
Journal:  Int J Legal Med       Date:  2014-08-14       Impact factor: 2.686

7.  Gene expression profiles of peripheral blood leukocytes after endotoxin challenge in humans.

Authors:  Shefali Talwar; Peter J Munson; Jennifer Barb; Carmen Fiuza; Anadel Pilar Cintron; Carolea Logun; Margaret Tropea; Sameena Khan; Debra Reda; James H Shelhamer; Robert L Danner; Anthony F Suffredini
Journal:  Physiol Genomics       Date:  2006-01-10       Impact factor: 3.107

Review 8.  Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis.

Authors:  B Rau; C M Krüger; M K Schilling
Journal:  Langenbecks Arch Surg       Date:  2004-03-06       Impact factor: 3.445

9.  Laboratory markers of systemic inflammation as predictors of bloodstream infection in acutely ill patients admitted to hospital in medical emergency.

Authors:  H Aalto; A Takala; H Kautiainen; H Repo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-10       Impact factor: 3.267

Review 10.  Role of biomarkers in sepsis care.

Authors:  Ravi S Samraj; Basilia Zingarelli; Hector R Wong
Journal:  Shock       Date:  2013-11       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.